



02050646

PE 8-12-02

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549


Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For 12 August, 2002

GlaxoSmithKline plc  
(Name of registrant)

GLAXOSMITHKLINE, 980 GREAT WEST ROAD,  
BRENTFORD, MIDDLESEX TW8 9GS  
(Address of principal executive offices)



PROCESSED

AUG 16 2002

THOMSON  
FINANCIAL

Indicated by check mark whether the registrant files or will file annual reports  
under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

CR



GlaxoSmithKline

**GlaxoSmithKline plc**

980 Great West Road  
Brentford  
Middlesex  
TW8 9GS

Tel. +44 (0)20 8047 5000

[www.gsk.com](http://www.gsk.com)

**Directors' Interests**

I give below details of a change in the interests in Ordinary Shares of GlaxoSmithKline plc in respect of the undermentioned Director arising from the purchase of Ordinary Shares at a price of £13.33 per Ordinary Share on 9 August 2002 through the Company's ShareReward Plan ("the Plan") which Mr Coombe entered on 5 October 2001:

Mr J D Coombe

Acquisition of 9 Ordinary Shares under the partnership element of the Plan (personal contribution)

Acquisition of 9 Ordinary Shares under the matching element of the Plan (Company contribution)

Mr Coombe and the Company were advised of this information on 12 August 2002.

S M Bicknell  
Company Secretary

12 August 2002



GlaxoSmithKline

**GlaxoSmithKline plc**

980 Great West Road  
Brentford  
Middlesex  
TW8 9GS

Tel. +44 (0)20 8047 5000  
[www.gsk.com](http://www.gsk.com)



### Directors' Interests

I give below details of changes in directors' interests in the Ordinary Shares of GlaxoSmithKline plc.

8 August 2002

The Administrators of the GlaxoSmithKline US Retirement Savings Plan ("the Plan") notified GlaxoSmithKline plc on the 12 August 2002, that as a result of movement in the fund on the 8 August 2002, the number of Ordinary Share ADRs held by the fund had decreased from 18,094,484 to 18,026,847 at an average price of \$41.86.


The Trust is a discretionary fund of which all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Two of the Company's directors, Dr J P Garnier and Mr J D Coombe are therefore interested in the shares held in the fund from time to time in the same way as other employees or former employees of GlaxoSmithKline plc and its subsidiaries.

S M Bicknell  
Company Secretary

12 August 2002



GlaxoSmithKline



**GlaxoSmithKline plc**

980 Great West Road  
Brentford  
Middlesex  
TW8 9GS

Tel. +44 (0)20 8047 5000  
www.gsk.com

**Directors' Interests**

I give below details of changes in directors' interests in the Ordinary Shares of GlaxoSmithKline plc.

9 August 2002      The Administrators of the SmithKline Beecham Employee Benefit Trust ("the Trust") notified the Company on the 12 August 2002 that 18,905 Ordinary shares had been transferred from the Trust to participants of the SmithKline Beecham 1991 Share Option Plan.

The Trust is a discretionary fund of which all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Two of the Company's directors, Dr J P Garnier and John Coombe are therefore interested in the shares held in the fund from time to time in the same way as other employees or former employees of GlaxoSmithKline plc and its subsidiaries.

S M Bicknell  
Company Secretary

12 August 2002

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: 12 August, 2002

By:

  
VICTORIA LLEWELLYN  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc